Lead Pb 212-MP0712

**Semantic type:** Pharmacologic Substance

**Definition:** A half-life engineered radioconjugate composed of MP0712, a designed ankyrin repeat proteins (DARPin)-based agent targeting the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), conjugated, through the bifunctional, macrocyclic chelating agent DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide; TCMC), to the alpha-emitting radioisotope lead Pb 212, with potential antineoplastic activity. Upon administration of lead Pb 212-MP0712, the DARPin moiety targets and binds to DLL3 expressed on tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to the DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation. DARPins are small, have favorable pharmacokinetics, allow for high tumor uptake and penetration, and have high binding affinity. MP0712 also binds to human serum albumin, which extends the half-life of MP0712.

**Synonyms:** - 212Pb-DOTAM-MAM279 - 212Pb-MP0712 - 212Pb-labeled MP0712 - DLL3-targeting 212Pb-based DARPin Therapeutic Agent MP0712 - Lead Pb 212 MP0712 - Lead Pb 212-DOTAM-MAM279 - Lead Pb 212-labeled DLL3-targeting DARPin MP0712 - Pb212-DOTAM-MAM279